Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Apogee Therapeutics, Inc.NASDAQ: APGE
Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Financing cash flow growth accelerates
Q2 FY2026 financing cash flow of $107.02M rose 8969.2% year over year, ahead of the +1861.4% change in trailing-twelve-month financing cash flow. Sequentially, it fell 74.0% from the prior quarter. Over 3 fiscal years it compounded at +33.1% a year.
Context
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +8969.2% holds above the trailing-twelve-month pace of +1861.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 396.49M USD
- Year-over-year change
- -19.9%
- 3-year CAGR
- +33.1%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 396.49M | -19.9% |
| FY2024 | 2024-12-31 | 495.11M | +57.0% |
| FY2023 | 2023-12-31 | 315.39M | +87.4% |
| FY2022 | 2022-12-31 | 168.32M | — |
Financing Cash Flow vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1861.4% is the 4th highest of 10, against a peer median of +81.4%.
- Over three fiscal years its annual growth of +33.1% compares with a peer median of +44.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | FY2025 | CN¥2.54B CNY | +707.0% | +60.1% | 454.8% |
| LTM Sep 2026 | $956.8M USD | +5992.0% | -25.1% | — | |
| LTM Jun 2026 | $912.87M USD | +1861.4% | +33.1% | — | |
| LTM Jun 2026 | $777.67M USD | +11487.0% | +44.2% | — | |
| LTM Sep 2026 | $504.27M USD | +81.4% | +8.7% | 8178.2% | |
| LTM Mar 2026 | $477.84M USD | +19.6% | -1.6% | 71.4% | |
| LTM Mar 2026 | $318.91M USD | -10.8% | +760.8% | — | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $256.89M USD | -10.0% | +47.0% | — |
| LTM Sep 2026 | $115.15M USD | +822385.3% | — | 8.5% | |
| LTM Jun 2026 | $44.64M USD | -86.6% | — | 9.9% | |
| Peer median (excluding APGE) | — | +81.4% | +44.2% | 71.4% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (39.79M) | (83.99M) | (182.15M) | (255.84M) |
| Depreciation & Amortization | 0 | 0 | 189K | 1.42M |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.14M | 6.1M | 23.33M | 46.28M |
| Change in Working Capital | 9.82M | 6.11M | (2M) | (15.48M) |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 418K | 1.61M | (1.07M) | 150K |
| Other Working Capital | 9.4M | 4.49M | (930K) | (15.63M) |
| Other Non-Cash Items | 11.4M | (2.98M) | (10.55M) | (3.82M) |
| Operating Cash Flow | (16.43M) | (74.76M) | (171.17M) | (227.45M) |
| Capital Expenditures | 0 | (167K) | (1.15M) | (5.15M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (303.74M) | (649.45M) | (642.3M) |
| Sales of Investments | 0 | 30M | 350.14M | 467.87M |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (273.91M) | (300.46M) | (179.57M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 168.32M | 315.39M | 493.48M | 396.49M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 1.63M | 0 |
| Financing Cash Flow | 168.32M | 315.39M | 495.11M | 396.49M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 151.89M | (33.28M) | 23.47M | (10.53M) |
| Free Cash Flow | (16.43M) | (74.93M) | (172.33M) | (232.6M) |
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.